The cytological mechanism and effects of hypertensive cerebral hemorrhage treatment by citicoline on serum GFAP and copeptin level

Zang, Jun; Liu, Aixian; Qi, Lin

doi:10.1177/2058739219867244

Cited by 6 publications

(9 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, on the BI scale, people from the research group obtained better results (69.28 vs. 51.57) ( p < 0.05). In both groups, all the parameters tested had a similar value at the beginning of the experiment [ 37 ].…”

Section: Resultsmentioning

confidence: 99%

Application of Citicoline in Neurological Disorders: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

Citicoline is a chemical compound involved in the synthesis of cell membranes. It also has other, not yet explained functions. Research on the use of citicoline is conducted in neurology, ophthalmology, and psychiatry. Citicoline is widely available as a dietary supplement. It is often used to enhance cognitive functions. In our article, accessible databases were searched for articles regarding citicoline use in neurological diseases. This article has a systemic review form. After rejecting non-eligible reports, 47 remaining articles were reviewed. The review found that citicoline has been proven to be a useful compound in preventing dementia progression. It also enhances cognitive functions among healthy individuals and improves prognosis after stroke. In an animal model of nerve damage and neuropathy, citicoline stimulated regeneration and lessened pain. Among patients who underwent brain trauma, citicoline has an unclear clinical effect. Citicoline has a wide range of effects and could be an essential substance in the treatment of many neurological diseases. Its positive impact on learning and cognitive functions among the healthy population is also worth noting.

show abstract

Section: Resultsmentioning

confidence: 99%

Application of Citicoline in Neurological Disorders: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…31 The COVID-19 pandemic can also cause another thing during the research, which resulted in a lack of research samples. Where in a study conducted by Zang et al (2019) which examined the relationship between giving citicoline injection to 102 patients with hemorrhagic stroke and GFAP levels showed a significant relationship (p = 0.000). 28 Another thing is made possible by the dose of enteral formula that is too small, the duration of administration, and the route of administration which can be the cause of the research results.…”

Section: Discussionmentioning

confidence: 98%

“…Where in a study conducted by Zang et al (2019) which examined the relationship between giving citicoline injection to 102 patients with hemorrhagic stroke and GFAP levels showed a significant relationship (p = 0.000). 28 Another thing is made possible by the dose of enteral formula that is too small, the duration of administration, and the route of administration which can be the cause of the research results. The doses in this study were 45 g protein/day, 384 mg/day phosphatidylcholine, 96 g/day phosphatidylserines, and 9 g/day inulin.…”

Section: Discussionmentioning

confidence: 98%

“…The results of previous studies showed that the level of GFAP in patients with ischemic stroke was 9.46 ng / mL (mean) and the standard deviation was 4.6 ng / mL. 28 The minimum difference considered significant (x1-x2) was 5.13 ng / mL. 28 If the error of type I is set at 15% (α=0.15) then Zα=1.440.…”

Section: Methodsmentioning

confidence: 99%

“…28 The minimum difference considered significant (x1-x2) was 5.13 ng / mL. 28 If the error of type I is set at 15% (α=0.15) then Zα=1.440. The amount of type II error is set at 20% (β=0.20) then Zβ=0.842 and research power is 80%, the sample size calculation is as follows:…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

The effect of addition protein, phosphatidylcholine, phosphatidylserine, and inulin on GFAP levels of acute ischemic stroke patients at Dr. Kariadi Hospital, Semarang

Wahyuningrum

Retnaningsih

Kartasurya

2021

JGI

View full text Add to dashboard Cite

Background: The occurrence of ischemia causes a loss of energy to switch to anaerobic processes resulting in acidosis due to reduced Adenosina Triphosphate (ATP). This condition makes neuron cells apoptotic. Apoptotic of several biochemical substrates in the brain, such as Glial Fibrillary Acidic Protein (GFAP) exit into the circulatory system which is associated with dysbiosis through immunological pathways.Objectives: To determine the effect of giving enteral formula containing protein, phosphatidylcholine, phosphatidylserine, and inulin on GFAP levels in patients with acute ischemic stroke Dr. Kariadi Hospital.Materials and Methods: This study was done in a single-blind RCT. Eighteen ischemic stroke patients were randomly divided into intervention (9 subjects) and control groups (9 subjects). The intervention group received 69 g of the powdered enteral formula three times a day for seven days. The formula contained protein (15 g), phosphatidylcholine (128 mg), phosphatidylserine (32 mg), and inulin (3 g). The subject who had diabetes mellitus received for 14 days at a dose of 34.5 g per day (7.5 g protein with additions 64mg phosphatidylcholine, 16mg phosphatidylserine, 1.5 g inulin). The control group received the standard enteral formula from the hospital, which contains (11.8 g protein without additions protein, phosphatidylcholine, phosphatidylserine, and inulin). GFAP levels by ELISA method (Enzyme-linked immunosorbent Assay) at pre and post-intervention.Results: There was a trend of decreasing GFAP levels before and after in the intervention group towards a better direction from 8.37±4.25 to 8.30±4.9 compared with the control group which experienced an increasing trend from 5.4±1.8 to 7.5±4. There was no significant difference in GFAP levels after intervention between groups (p = 0.7).Conclusions: The addition of protein, phosphatidylcholine, phosphatidylserine, and inulin had no significant effect on GFAP levels.

show abstract

Serum Levels of the Biomarkers Associated with Astrocytosis, Neurodegeneration, and Demyelination: Neurological Benefits of Citicoline Treatment of Patients with Ischemic Stroke and Atrial Fibrillation

Kuryata¹,

Kushnir²,

Nedzvetsky

et al. 2021

Neurophysiology

View full text Add to dashboard Cite

Ischemic stroke is a main complication of atrial fibrillation (cardiac arrhythmia). The aim of our study was to estimate the effects of citicoline (CDP-choline) therapy on the levels of circulating neurospecific protein markers in serum of the patients with ischemic stroke and atrial fibrillation. Fiftyfour patients (mean age 76 years) treated with citicoline in a dose of 2.0 g daily intravenously for 12 to 14 days in addition to basic treatment formed the examined group. Thirty-two patients (mean age 68.5 years) obtained only standard therapy and formed the control group. Serum levels of neuronal and glial protein markers, including glial fibrillary acidic protein (GFAP), a neurofilament light subunit (NF-L), myelin basic protein (MBP), and ionized calcium-binding adaptor molecule 1 (Iba1), were measured in patients of both groups before and after treatment; an immunoblotting technique followed by densitometry analysis were used. Supplementary citicoline treatment provided significant reductions of the levels of GFAP (33%, P = 0.034), NF-L (27%, P = 0.019), and MBP (32%, P = 0.018), as compared to the initial values, while there were no marked changes in the studied parameters in the control group. The results obtained allow us to hypothesize that therapeutic benefit of citicoline in patients with ischemic stroke and atrial fibrillation can be mediated through increasing neuronal viability, protecting against axonal injury, decreasing the level of reactive astrogliosis, preventing deficiencies in the blood-brain integrity, and reducing the intensity of demyelination. However, citicoline administration exerted no effect on the blood content of microglial marker Iba-1, thus possibly preserving an important functional significance of microglia, which is needed to resolve local inflammation and clear cellular debris, and also provide protective factors to reduce cell injury in the ischemic brain. The obtained results indicate that serum levels of neurospecific biomarkers are significant and clinically relevant indices of the efficiency of treatment of the above-mentioned pathologies and can be used for further investigations of the stroke pathophysiology and molecular mechanisms of nootropic-mediated neuroprotection.

show abstract

The cytological mechanism and effects of hypertensive cerebral hemorrhage treatment by citicoline on serum GFAP and copeptin level

Cited by 6 publications

References 10 publications

Application of Citicoline in Neurological Disorders: A Systematic Review

Application of Citicoline in Neurological Disorders: A Systematic Review

The effect of addition protein, phosphatidylcholine, phosphatidylserine, and inulin on GFAP levels of acute ischemic stroke patients at Dr. Kariadi Hospital, Semarang

Serum Levels of the Biomarkers Associated with Astrocytosis, Neurodegeneration, and Demyelination: Neurological Benefits of Citicoline Treatment of Patients with Ischemic Stroke and Atrial Fibrillation

Contact Info

Product

Resources

About